Introduction
Chronic lymphocytic leukaemia (CLL) is a mature, clonal B-cell neoplasm for which the underlying molecular pathogenesis is incompletely understood. It is the most frequent type of leukaemia in the Western world, accounting for about 30% of cases. Although CLL is considered to be incurable, patients with this disease undergo various diverse clinical courses: some survive for decades with little or no treatment while others progress rapidly. The familial incidence is nearly three times higher than is expected for the general population, and one predisposing factor might be an inherited partial failure of mechanisms involved in lymphocytes apoptosis, resulting in the progressive accumulation of mature CD5 þ B lymphocytes in the blood and marrow of affected individuals. 1, 2 Recently the status of the P2X7 receptor, a plasma membrane ATP-gated ion channel that is expressed on haemopoietic cells, has emerged as one possible factor that may predispose to CLL or influence the clinical course of this disease. Whereas short stimulation of the receptor by ATP is believed to facilitate the passage of cations and promote proliferation, strong or prolonged stimulation enables the passage of larger molecules that may act as a trigger for apoptosis. [3] [4] [5] A common singlenucleotide polymorphism (SNP) within the P2X7 gene has been described in exon 13 (nucleotide 1513A to C), which results in the substitution of glutamic acid at amino-acid position 496 by alanine (E496A). This polymorphism occurs in the region of the gene that encodes the carboxy-terminal tail of the protein, a structure that controls the permeability properties of the P2X7 receptor, 4 and biochemical studies have demonstrated that homozygosity for the C allele (C / C) leads to almost complete loss of P2X7 function, whereas heterozygosity (A / C) give a function that is half that of cells with the germline (A / A) P2X7 sequence. 5, 6 In a small study of Australian CLL patients with relatively indolent disease, the C allele was found to be three-fold more prevalent in affected individuals compared to normal controls, suggesting that inheritance of the C allele might predispose to development of CLL. 6 A larger study from Sweden of patients with relatively aggressive disease failed to confirm this finding, 7 but patients with the C allele (A/C) who had mutated IGVH genes, currently one of the best molecular indicators of outcome in CLL, [8] [9] [10] were found to survive significantly longer than those who were A/A. A third study found that expression levels and function of P2X7 was higher in lymphocytes from CLL patients with progressive disease compared to those with more indolent disease.
11 Taken together, these three studies suggest that P2X7 may play an important role in the aberrant proliferation and/or apoptosis of CLL cells. In addition, the gene encoding P2X7 is located on chromosome 12. Trisomy of this chromosome is one of the most common cytogenetic aberrations in CLL and is associated with atypical morphology of lymphocytes, progressive disease and poor survival. 12 Our aim in this study was to assess the significance of P2X7 receptor in the UK by (i) comparing the frequency of the C and A alleles in CLL patients and healthy controls and (ii) analysing the association between P2X7 genotype and clinical outcome or chromosome 12 status in CLL.
Patients and methods

Patients and controls
DNA was analysed from 144 patients with CLL diagnosed on standard morphological and immunophenotypic criteria. 13 All patients have been previously characterised with regard to IgVH mutational status and trisomy for chromosome 12 by karyotype and FISH. 10 As controls, DNA was analysed from 348 firstdegree relatives of individuals ascertained for a variety of genetic conditions in the Wessex region.
Genotype assay
The P2X7 genotype for patients and controls were analysed by using a tetraprimer amplification refractory mutation system (ARMS) assay. This method employs two primer pairs to amplify the two different alleles of a SNP plus a positive control band in a single reaction.
14 Primers were designed by using tetra-primer ARMS-PCR primer design programme (http://cedar.genetics.soton.ac.uk/public_html/primer1.html) 14 and include mismatches to maximise discrimination of the two alleles (shown in lower case). PCR primers were: forward outer (FO), 5 0 -TGGACTTCACAGATTTGTCCAGGCTGCCCC-3 0 ; reverse outer (RO), 5-CAAAGTCAGCCATGTCCTGGGAGCC GAAGC-3 0 ; forward inner C allele (FIC), 5 0 -ACTCCCTGA GAGCCACAGGTGCCTGGAaGC-3 0 ; reverse inner A allele (RIA), 5 0 -CCCCGGCTTTTTCCGGCAGCACAaCT-3 0 . Amplifications were performed for 35 cycles with HotStart Taq polymerase (Qiagen), an annealing temperature of 681C, 25 ng genomic DNA and standard conditions except that the concentrations of primers were: FO, 0.3 mM; RO, 0.3 mM; FIC, 2 mM; RIA, 0.5 mM. The products were resolved on 2% agarose gel and visualised after staining with ethidium bromide.
Genotypes in selected cases were validated by direct sequencing using the BigDyet Termination Cycle Sequencing Reaction Kit (Applied Biosystems) and an automated sequencer (ABI 3100; Applied Biosystems) (n ¼ 24) or by digestion with HhaI (which cuts the C allele) and AluI (which cuts the A allele) restriction enzymes (n ¼ 22). All results were completely concordant. Positive controls for A/A, A/C and C/C genotypes were amplified for each run of the ARMS assay and occasional reactions that failed to give rise to a clear control band were repeated, if necessary with an independent DNA sample. The configuration of PCR primers and representative results are shown in Figure 1 .
Comparative sequence analysis
Comparative sequence analysis (CSA) 15 was used to compare the sequence traces of A/C heterozygotes with or without trisomy 12. For patients with þ 12, deviations in the raw A or C peak height by three or more standard deviations from that seen in normal individuals was defined as significant.
Statistical analysis
Fisher's exact test was used to examine the differences in P2X7 genotype frequencies between patients and controls, association between genotype and chromosome 12 aneuploidy. Time to death data was analysed using Kaplan-Meier survival curves.
Comparison of survival curves between two or more groups of patients were made using log-rank tests.
Results and discussion
Genotypes of patients and controls
Of the 144 patients with CLL, 98 (68%) had an A/A genotype, 42 (29%) were A/C and four (3%) were C/C. No difference in allele frequencies was seen between the CLL and the control group: of the 348 controls, 232 (67%) were A/A, 105 (30%) were A/C and 11 (3%) were C/C (P ¼ 0.83; Table 1 ). Since the median age of the control group (median 33 years, range 10-90) was younger than the CLL patients (median age 66 years, range 28-93), we evaluated the effect of age by comparing the genotypes of controls who were younger than 50 years (n ¼ 235, median age 29 years) or older than 50 years (n ¼ 113, median age 58 years). No differences in P2X7 allele frequencies were seen between the two control groups, or between either control group and patients with CLL (Table 2) .
CLL P2X7 genotype and clinical outcome
To determine if P2X7 genotype is associated with clinical outcome, we compared the survival of patients who were A/A (n ¼ 98; median follow up 97 months) with those who were heterozygous or homozygous for the C allele (n ¼ 46; median follow up 80 months). As shown in Figure 2 , there was no difference in survival between the two groups (P ¼ 0.39).
In CLL, the median survival is approximately 8 years for patients with unmutated IGVH genes and approximately 25 years for patients with mutated IGVH genes.
8-10 Figure 3 shows the survival of mutated (n ¼ 100) or unmutated (n ¼ 44) subsets of patients according to the P2X7 genotype. Although there was a trend towards shorter survival in both mutated and unmutated patients who harboured at least one C allele, the difference was not significant (P ¼ 0.17 for mutated cases, P ¼ 0.25 for unmutated cases).
CLL P2X7 genotype and trisomy of chromosome 12
Since the P2X7 gene is located on chromosome 12, and gain of this chromosome is a recurrent abnormality in CLL, we determined if there was any relationship between chromosome 12 status and P2X7 genotype. Of the 40 patients in this study who had an additional copy of chromosome 12, 31 cases (78%) were A/A and nine (22%) cases were A/C. Of the 104 patients without trisomy 12, 67 (64%) were A/A and 37 (36%) were A/C or C/C. The difference between the allele frequencies and occurrence of trisomy 12 was not significant (P ¼ 0.30).
To determine if P2X7 genotype influences which of the two copies of chromosome 12 is duplicated in patients with trisomy 12, we compared the sequence traces of nine A/C heterozygotes with trisomy 12 to normal heterozygotes by CSA. Of the nine A/C heterozygotes with þ 12, four were found to have gained an extra copy of the A chromosome (A/A/C), four had gained an extra copy of the C chromosome (A/C/C) and one did not show a significant deviation from normal.
Overall, then we have not found any significant relationship between P2X7 genotype and either incidence, outcome or abnormalities of chromosome 12 in CLL. This contrasts with previous studies that found the C allele to be more prevalent in affected individuals compared to normal controls, 6 or the C allele to be associated with longer survival. 7 The patients studied here are derived from the local population and therefore the majority have relatively indolent disease and mutated IGVH genes. This is similar to the patients in the Australian study, 6 the main difference being that our analysis included a greater number of patients and controls. Regarding survival, it is possible that any effect of P2X7 genotype is only manifest in patients with progressive disease, as analysed in the Swedish study. 7 Subsequent multivariate analysis, however, showed that P2X7 genotype was not an independent prognostic variable, 16 suggesting that the prognostic effect may be linked to the finding IGVH mutational status. However, we did not find any difference in P2X7 genotype frequency or any difference in outcome with regard to genotype in mutated or unmutated subsets. We conclude therefore that the influence of P2X7 genotype on incidence or outcome in CLL is either nonexistent or small. 
